EcoDrugPlus

Tyrosine-Protein Kinase Receptor Tie-1-Like

Ensembl ID : ENSNBRG00000018998
Gene Symbol: LOC102791181
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo-Like

Ensembl ID : ENSNBRG00000005312
Gene Symbol: LOC102780129
2 Cross references
187 Possible Orthologues:

Tyrosine-Protein Kinase Yes-Like

Ensembl ID : ENSNBRG00000009820
Gene Symbol: LOC102800169
3 Cross references
206 Possible Orthologues:

Tyrosine-Protein Phosphatase Non-Receptor Type 11-Like

Ensembl ID : ENSNBRG00000018685
Gene Symbol: LOC102798298
3 Cross references
251 Possible Orthologues:

Ubiquitin-Like Protein Fubi-Like

Ensembl ID : ENSNBRG00000021496
Gene Symbol: LOC102796466
3 Cross references
300 Possible Orthologues:

Uncharacterized Loc102793375

Ensembl ID : ENSNBRG00000005429
Gene Symbol: LOC102793375
2 Cross references
196 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSNBRG00000016317
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

Utrophin-Like

Ensembl ID : ENSNBRG00000018130
Gene Symbol: LOC102778896
2 Cross references
269 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSNBRG00000011601
Gene Symbol: RELA
1 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSNBRG00000021135
Gene Symbol: LOC102788350
3 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor Receptor 1-Like

Ensembl ID : ENSNBRG00000023280
Gene Symbol: LOC102787463
3 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor Receptor 2-Like

Ensembl ID : ENSNBRG00000003289
Gene Symbol: LOC102779264
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).